At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADIL Adial Pharmaceuticals
Market Closed 08-21 16:00:00 EDT
6.22
+0.32
+5.34%
盘后6.03
-0.18-2.98%
19:30 EDT
High6.41Low5.74Vol81.99K
Open5.95D1 Closing5.90Amplitude11.36%
Mkt Cap16.32MTradable Cap15.82MTotal Shares2.63M
T/O493.98KT/O Rate3.22%Tradable Shares2.55M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
TIPRANKS  ·  08-22 06:02
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
Adial Pharmaceuticals Gets NASDAQ Notice for Falling Below $2.5 Million Stockholders’ Equity Minimum
Reuters  ·  08-22 05:18
Adial Pharmaceuticals Gets NASDAQ Notice for Falling Below $2.5 Million Stockholders’ Equity Minimum
U.S. Stocks on the MOVE - Sunrun, JetBlue Airways, Dell Technologies
Reuters  ·  08-17
U.S. Stocks on the MOVE - Sunrun, JetBlue Airways, Dell Technologies
U.S. Stocks on the MOVE - KBR, Vista Energy, Fulcrum Therapeutics
Reuters  ·  08-17
U.S. Stocks on the MOVE - KBR, Vista Energy, Fulcrum Therapeutics
Adial Pharmaceuticals Q2 EPS $(11.25)
Benzinga Earnings  ·  08-17
Adial Pharmaceuticals Q2 EPS $(11.25)
Adial Pharmaceuticals Falls After Quarterly Loss Widens
Reuters  ·  08-17
Adial Pharmaceuticals Falls After Quarterly Loss Widens
Adial Pharmaceuticals Posts Bigger-than-Expected Q2 Net Loss, Hurt by Acquisition Charges
Reuters  ·  08-17
Adial Pharmaceuticals Posts Bigger-than-Expected Q2 Net Loss, Hurt by Acquisition Charges
Adial Pharmaceuticals Q2 Net Income USD -52 Million
THOMSON REUTERS  ·  08-17
Adial Pharmaceuticals Q2 Net Income USD -52 Million
Press Release: Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
Dow Jones  ·  08-17
Press Release: Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  08-17
Calendar of U.S. Earnings Expected in the Week Ahead
Adial Pharma Faces Governance Risks and Major Dilution as 2026 Shareholder Vote Looms on Preferred Conversions and Warrants
TIPRANKS  ·  08-16
Adial Pharma Faces Governance Risks and Major Dilution as 2026 Shareholder Vote Looms on Preferred Conversions and Warrants
Adial Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-15
Adial Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Adial Q2 Net Loss Widens to $51.99 Million from Year-Ago Quarter
Reuters  ·  08-15
Adial Q2 Net Loss Widens to $51.99 Million from Year-Ago Quarter
Adial Pharmaceuticals Plans Major Leadership and Board Transition
TIPRANKS  ·  08-14
Adial Pharmaceuticals Plans Major Leadership and Board Transition
Adial Pharmaceuticals - as of Aug 10, Anticipates Termination of CEO Cary Claiborne After 2026 Annual Meeting
Reuters  ·  08-14
Adial Pharmaceuticals - as of Aug 10, Anticipates Termination of CEO Cary Claiborne After 2026 Annual Meeting
Adial Pharmaceuticals - Anticipates Board Changes and Legacy Member Resignations After Stockholder Approval - SEC Filing
THOMSON REUTERS  ·  08-14
Adial Pharmaceuticals - Anticipates Board Changes and Legacy Member Resignations After Stockholder Approval - SEC Filing
Adial Pharmaceuticals - Anticipates Termination of CFO Vinay Shah After 2026 Annual Meeting - SEC Filing
THOMSON REUTERS  ·  08-14
Adial Pharmaceuticals - Anticipates Termination of CFO Vinay Shah After 2026 Annual Meeting - SEC Filing
Adial Pharmaceuticals CEO Cary Claiborne Set to Depart After Sept. 17 Annual Meeting; CDO Matthew Davidson Slated to Succeed
Reuters  ·  08-14
Adial Pharmaceuticals CEO Cary Claiborne Set to Depart After Sept. 17 Annual Meeting; CDO Matthew Davidson Slated to Succeed
Adial Pharmaceuticals Announces Annual Shareholder Meeting
Reuters  ·  08-11
Adial Pharmaceuticals Announces Annual Shareholder Meeting
Adial Pharmaceuticals Inc Expected to Post a Loss of $1.03 a Share - Earnings Preview
Reuters  ·  08-08
Adial Pharmaceuticals Inc Expected to Post a Loss of $1.03 a Share - Earnings Preview

Introduction

Company Name.
Adial Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Issue price:
--